Overview

* Interpace Q3 revenue falls 29% yr/yr, but rises 22% from pro forma results

* Company reports record thyroid test volumes and cash collections in Q3

* Interpace focuses on lab efficiency and AI, supporting strategic investments

Outlook

* Company did not provide specific future guidance in press release

Result Drivers

* RECORD THYROID TEST VOLUME - Co achieved record thyroid test volumes, driven by higher testing activity and improved reimbursement strategies

* LAB EFFICIENCY INVESTMENTS - Strategic investments in AI and automation improved lab operational efficiency and strengthened balance sheet

* THYROID-ONLY FOCUS - Transition to thyroid-only diagnostics business contributed to revenue growth compared to pro forma results

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $8.76

Revenue mln

Q3 Net $911,000

Income

Q3 Gross $5.44

Profit mln

Q3 $4.29

Operatin mln

g

Expenses

Q3 $1.15

Operatin mln

g Income

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)